1303967-81-8

Basic information

• Product Name: tert-butyl 2-((isopropylamino)methyl)pyrrolidine-1-carboxylate
• Synonyms: tert-butyl 2-((isopropylamino)methyl)pyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 2-[[(1-methylethyl)amino]methyl]-, 1,1-dimethylethyl ester
• CAS NO: 1303967-81-8
• Molecular Formula: C13H26N2O2
• Molecular Weight: 242
• Mol File: 1303967-81-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 2-((isopropylamino)methyl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-((isopropylamino)methyl)pyrrolidine-1-carboxylate(1303967-81-8)
• EPA Substance Registry System: tert-butyl 2-((isopropylamino)methyl)pyrrolidine-1-carboxylate(1303967-81-8)

Safety Data

• Hazardous Substances Data: 1303967-81-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl 2-((isopropylamino)methyl)pyrrolidine-1-carboxylate is a chemical compound with potential pharmaceutical applications. It is a derivative of pyrrolidine and contains a tert-butyl ester group. The compound also features an isopropylamino group, which suggests potential pharmacological activity related to the central nervous system. Due to its structural features and potential biological activity, tert-butyl 2-((isopropylamino)methyl)pyrrolidine-1-carboxylate could be of interest for medicinal chemistry research and drug development efforts. Additional studies may be needed to further explore its properties and potential applications in pharmacology.

Upstream product

• 67-64-1 acetone 
• 259537-92-3 tert-butyl (2R)-2-(aminomethyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein Rl is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6balkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.